Research programme: antibody diagnostics and therapeutics - Immunomedics

Drug Profile

Research programme: antibody diagnostics and therapeutics - Immunomedics

Alternative Names: (14)-3s; (19)-3s; (E1)-3s; (M1)-3s; 20-(74)-(74) antibody; 20-2b; 74-(20)-(20) antibody; Anti-CD19 antibodies; anti-CD20/CD74 antibodies; bsMAb; Ck-20-2b; CK-22-(20)-(20); E1.BB.3z-92MI; MAb-Rap; TF 12; TF 3; TF 4; TF 5; Veltuzumab-interferon-α2b conjugate

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Bispecific antibodies; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Recombinant fusion proteins; Ribonucleases
  • Mechanism of Action Apoprotein stimulants; Glycoprotein modulators; Ionising radiation emitters; Mitosis inhibitors; Protein synthesis inhibitors; Ribonuclease stimulants; T lymphocyte stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Gastric cancer; Lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 23 Feb 2017 Immunomedics plans a phase I trial for Cancer with bispecific antibodies
  • 06 Jan 2017 Preclinical development is ongoing in USA for Cancer, Lymphoma, and Solid tumours
  • 12 Dec 2016 Preclinical trials in Breast cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top